Loading...
XNAS
ISPC
Market cap352kUSD
Jul 09, Last price  
2.54USD
1D
10.92%
1Q
-50.43%
IPO
-99.96%
Name

iSpecimen Inc

Chart & Performance

D1W1MN
XNAS:ISPC chart
P/E
P/S
0.18
EPS
Div Yield, %
Shrs. gr., 5y
150.35%
Rev. gr., 5y
-25.10%
Revenues
2m
-79.24%
4,394,8184,298,3508,184,10611,135,30310,402,3039,928,1849,291,1151,928,998
Net income
-10m
L-16.09%
-5,347,052-4,727,050-4,652,084-8,961,815-10,245,922-11,099,488-12,497,805-10,487,532
CFO
-4m
L-48.68%
-2,681,749-2,679,900-288,380-10,668,410-5,817,720-5,807,550-8,263,713-4,240,608

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.
IPO date
Jun 17, 2021
Employees
75
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT